In this Pharmaceutical Executive article, Thomas Swalla, CEO of Dotmatics, highlights the crucial role of intellectual property (IP) in the pharmaceutical industry, juxtaposed against the current buzz around artificial intelligence (AI).
While AI plays a crucial role in expediting drug development, true innovation lies in aligning drug candidates with specific diseases, a process deeply rooted in IP. In this thought-provoking piece, Thomas urges life sciences companies to prioritize data management and digital transformation, underscoring the intricate relationship between data, IP, and AI in advancing R&D.
Read the full article to learn how Dotmatics is at the forefront of this exciting intersection of technology and healthcare.
Learn More About Dotmatics
Meet with a product expert to see how Dotmatics uses AI technologies to drive down the cost of drug discovery.